Brian Harris, MedRhythms CEO

Bio­gen taps dig­i­tal ther­a­peu­tics biotech for mu­sic-based ther­a­py to help peo­ple with MS im­prove their walk­ing

In the past decade, dig­i­tal health­care has been get­ting big — and now it’s sad­dling up with Big Phar­ma. As the lat­est phar­ma to take a swing at dig­i­tal ther­a­py, Bio­gen has li­censed an in­ves­ti­ga­tion­al pre­scrip­tion ther­a­py meant to help pa­tients with mul­ti­ple scle­ro­sis (MS) im­prove their gait from MedRhythms, a Port­land, ME-based biotech.

For the ther­a­py, dubbed MR-004, MedRhythms is re­ceiv­ing $3 mil­lion up­front and can get up to $117.5 mil­lion more in down­stream mile­stones, ac­cord­ing to the press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.